Form 4 for SPRO Spero Therapeutics, Inc.
Accepted 2024-11-12 00:00:00 ET · period of report 2024-11-07 · accession 0000950170-24-125339 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-11-12 | 2024-11-07+ | SPRO | Rajavelu Esther | CFO, CBO | S - Sale | $1.31 | -40.6K | 396.5K | -9% | -$53.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-08 | S | D | 17,245 | $1.30 | 379,270 | D | — | — | |
| 2 | Common | Common Stock | 2024-11-07 | S | D | 23,351 | $1.31 | 396,515 | D | — | — |